Joanna Kopecka

List of Publications by Citations

73 papers	1,992 citations	29 h-index	42 g-index
80 ext. papers	2,548 ext. citations	8.6 avg, IF	4.94 L-index

#	Paper	IF	Citations
73	Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. *Molecular Pharmaceutics*, **2011**, 8, 683-700	5.6	81
72	PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. *Molecular Cancer*, **2017**, 16, 91	42.1	78
71	Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. *Oncotarget*, **2015**, 6, 6776-93	3.3	77
70	Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. *Molecular Cancer*, **2013**, 12, 137	42.1	66
69	ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	62
68	iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. *Molecular Cancer*, **2009**, 8, 108	42.1	61
67	Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. *Current Drug Metabolism*, **2013**, 14, 625-40	3.5	60
66	Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. *Drug Resistance Updates*, **2020**, 49, 100670	23.2	58
65	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. *Molecular Cancer Therapeutics*, **2016**, 15, 2640-2652	6.1	57
64	Pleiotropic effects of cardioactive glycosides. *Current Medicinal Chemistry*, **2011**, 18, 872-85	4.3	54
63	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. *Molecular Pharmaceutics*, **2013**, 10, 161-74	5.6	52
62	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. *Biochemical Journal*, **2011**, 439, 141-9	3.8	52
61	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. *Drug Resistance Updates*, **2020**, 53, 100718	23.2	52
60	Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/-catenin pathway. *Neuro-Oncology*, **2013**, 15, 1502-17	1	51
59	Multi-walled carbon nanotubes directly induce epithelial-mesenchymal transition in human bronchial epithelial cells via the TGF-mediated Akt/GSK-3/SNAIL-1 signalling pathway. *Particle and Fibre Toxicology*, **2016**, 13, 27	8.4	51
58	A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. *Journal of Controlled Release*, **2011**, 149, 196-205	11.7	48
57	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. *Pharmaceutics*, **2020**, 12,	6.4	47

56	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. *Journal of Controlled Release*, **2018**, 270, 37-52	11.7	47
55	Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. *PLoS ONE*, **2013**, 8, e60975	3.7	46
54	The ATP-binding cassette transporter A1 regulates phosphoantigen release and V9V2 T cell activation by dendritic cells. *Nature Communications*, **2017**, 8, 15663	17.4	39
53	Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. *Cancer Letters*, **2015**, 360, 219-26	9.9	38
52	Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling. *Cellular and Molecular Life Sciences*, **2014**, 71, 499-516	10.3	38
51	The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 1258-69	7.3	34
50	The role of C/EBP-LIP in multidrug resistance. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	32
49	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. *Oncotarget*, **2015**, 6, 31461-78	3.3	32
48	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. *Cellular and Molecular Life Sciences*, **2019**, 76, 609-625	10.3	32
47	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. *Pharmacological Research*, **2017**, 117, 67-74	10.2	31
46	Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2014**, 10, 77-87	6	31
45	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2019**, 14, 1458-1471	8.9	29
44	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. *OncoImmunology*, **2018**, 7, e1398874	7.2	29
43	B Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	28
42	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. *Oncotarget*, **2016**, 7, 20753-72	3.3	28
41	Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. *Cells*, **2020**, 9,	7.9	28
40	Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. *Molecular Pharmaceutics*, **2014**, 11, 3068-79	5.6	27
39	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. *Cancer Letters*, **2019**, 456, 29-39	9.9	26

38	Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma. *Molecular Cancer Therapeutics*, **2018**, 17, 2598-2609	6.1	26
37	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. *Biochemical Journal*, **2012**, 447, 301-11	3.8	24
36	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. *Oncotarget*, **2015**, 6, 1128-42	3.3	24
35	P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. *Oncotarget*, **2016**, 7, 85861-85875	3.3	24
34	HIF-1 s over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 1042-1054	6.6	23
33	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. *PLoS ONE*, **2015**, 10, e0126159	3.7	21
32	Increasing intratumor C/EBP- LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 286	12.8	21
31	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. *Journal of Medicinal Chemistry*, **2019**, 62, 4174-4192	8.3	20
30	Wnt/IL-1 IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. *International Journal of Cancer*, **2020**, 146, 192-207	7.5	20
29	Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 1492-504	5.6	19
28	Loss of C/EBP- LIP drives cisplatin resistance in malignant pleural mesothelioma. *Lung Cancer*, **2018**, 120, 34-45	5.9	16
27	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 580	5.6	16
26	Effects of Chrysotile Exposure in Human Bronchial Epithelial Cells: Insights into the Pathogenic Mechanisms of Asbestos-Related Diseases. *Environmental Health Perspectives*, **2016**, 124, 776-84	8.4	15
25	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 28	12.8	15
24	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. *Cells*, **2020**, 9,	7.9	13
23	Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. *Cells*, **2020**, 9,	7.9	11
22	Cholesterol metabolism: At the cross road between cancer cells and immune environment. *International Journal of Biochemistry and Cell Biology*, **2020**, 129, 105876	5.6	10
21	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. *Molecules*, **2018**, 23,	4.8	9

20	MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
19	Hypoxia as a driver of resistance to immunotherapy. *Drug Resistance Updates*, **2021**, 100787	23.2	8
18	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. *Seminars in Cell and Developmental Biology*, **2020**, 98, 80-89	7.5	8
17	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). *European Journal of Medicinal Chemistry*, **2020**, 188, 112037	6.8	7
16	Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. *Journal of Medicinal Chemistry*, **2021**, 64, 12132-12151	8.3	6
15	Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models. *Cellular Oncology (Dordrecht)*, **2021**, 44, 1307-1323	7.2	6
14	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
13	Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. *Pharmacological Research*, **2021**, 175, 105975	10.2	3
12	Targeting HIF-1 Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. *Cancers*, **2021**, 13,	6.6	3
11	Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells.. *Frontiers in Physiology*, **2021**, 12, 813547	4.6	1
10	Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors.. *Pharmaceutics*, **2022**, 14,	6.4	1
9	Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. *Bioorganic Chemistry*, **2021**, 119, 105514	5.1	1
8	Endothelial Heme Dynamics Drive Cancer Cell Metabolism by Shaping the Tumor Microenvironment. *Biomedicines*, **2021**, 9,	4.8	1
7	Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer. *Pharmaceutics*, **2021**, 13,	6.4	1
6	The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells.. *Drug Resistance Updates*, **2022**, 62, 100833	23.2	1
5	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 75	12.8	0
4	Nitric Oxide Reinstates Doxorubicin Cytotoxic and Proimmunogenic Effects in Refractory Breast Cancer **2019**, 325-326		
3	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. *Blood*, **2015**, 126, 2925-2925	2.2	

2	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells. *Blood*, **2016**, 128, 3709-3709	2.2
1	HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. *Blood*, **2016**, 128, 305-305	2.2